Umbralisib monotherapy demonstrates efficacy and safety in patients with relapsed/refractory marginal zone lymphoma: A multicenter, open-label, registration directed Phase II study

Authors
Category Primary study
JournalCancer Research
Year 2019
This article has no abstract
Epistemonikos ID: 6f4d403d4819371aa1d2f7f34abda544f87afb4d
First added on: Feb 11, 2025